Atrium Therapeutics Doses First Patient in Corventis™, the First Interventional Clinical Trial for People Living with PRKAG2 Syndrome

Article summary

-- Global Phase 1/2 trial will evaluate ATR 1072 in approximately 37 participants -- -- Initial proof of concept data expected in second half of 2027 -- SAN DIEGO, Oct. 27, 2026 — Atrium Therapeutics, Inc. (Nasdaq: RNA) (the "Company"), a biopharmaceutical company advancing...